狄诺塞麦推荐使用量是多少？

Injections are mainly used. Prefilled syringe: 60 mg/1 ml; injection: 60 mg/1 ml; 120 mg/1.7 ml. What is the recommended dosage of denosumab?

(1) Denosumab can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. (2) Recommended dosage of denosumab for the treatment of bone metastasis of solid tumors: 120 mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) The recommended dosage of denosumab for the treatment of giant cell tumor of bone: 120 mg once every 4 weeks by subcutaneous injection, and then 120 mg on day 8 and day 15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Recommended dosage of denosumab for the treatment of malignant hypercalcemia: 120 mg once every 4 weeks, subcutaneous injection, and another 120 mg on day 8 and day 15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Other medications with similar active ingredients to denosumab should be avoided while receiving denosumab. If a patient misses a dose of denosumab, it should be taken as soon as possible and six months after the missed dose. Patients with hypocalcemia should correct hypocalcemia before receiving this product; patients who are prone to hypocalcemia and mineral disorders in the body should undergo clinical monitoring of blood calcium and mineral levels and take appropriate amounts of calcium tablets and vitamin D when receiving this product.

Use can lead to serious infections such as skin infections, abdominal infections, urinary tract infections, and ear infections. Patients receiving this product should seek medical observation immediately if they develop signs or symptoms of serious infections. Taking it with immunosuppressants or drugs that damage the immune system can increase the risk of serious infection. Patients with serious infections need to weigh the pros and cons of using this product. Patients receiving denosumab are more likely to develop dermatitis, eczema and other skin reactions than patients in the placebo group. Once severe skin reactions occur, administration should be stopped immediately.